Literature DB >> 12436244

Hereditary haemochromatosis: only 1% of adult HFEC282Y homozygotes in South Wales have a clinical diagnosis of iron overload.

C Anne McCune1, Layla N Al-Jader, Alison May, Sara L Hayes, Helen A Jackson, Mark Worwood.   

Abstract

In northern Europe, about 90% of patients with hereditary haemochromatosis (HH) are homozygous for a single mutation (C282Y) of the HFEgene and approximately 1 in 150 people in the general population carries this genotype. However, the clinical significance of HFE mutations remains uncertain, as is the proportion of people homozygous for C282Y who will develop clinical symptoms leading to a diagnosis of HH. A systematic review of patients with HH over a 2-year period within a defined UK region has revealed that only 1.2% of adult C282Y homozygotes have been diagnosed with iron overload and received treatment. In those in whom body iron load could be estimated, only 51% has more than 4 g iron (the diagnostic threshold for iron overload).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12436244     DOI: 10.1007/s00439-002-0824-1

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  18 in total

1.  The origin and spread of the HFE-C282Y haemochromatosis mutation.

Authors:  S Distante; K J H Robson; J Graham-Campbell; A Arnaiz-Villena; P Brissot; Mark Worwood
Journal:  Hum Genet       Date:  2004-09       Impact factor: 4.132

2.  External quality assurance of molecular analysis of haemochromatosis gene mutations.

Authors:  M Hertzberg; S Neville; D McDonald
Journal:  J Clin Pathol       Date:  2006-05-05       Impact factor: 3.411

3.  Heteroduplex analysis for the three common HFE variants: methodology, reliability and analysis of over 5000 requests for testing.

Authors:  Jeanne Kingston; Derrick Bowen; Marion Sweeney; Susan Lawless; Helen Jackson; Mark Worwood
Journal:  J Clin Pathol       Date:  2006-11-01       Impact factor: 3.411

4.  [Genetics and quaternary prevention. The example of haemochromatosis].

Authors:  J Gérvas; M Pérez Fernández
Journal:  Aten Primaria       Date:  2003       Impact factor: 1.137

5.  Clinical utility gene card for: Haemochromatosis [HFE].

Authors:  Manfred Stuhrmann; Heinz Gabriel; Stephen Keeney
Journal:  Eur J Hum Genet       Date:  2010-02-03       Impact factor: 4.246

6.  Targeted screening for genetic haemochromatosis: a combined phenotype/genotype approach.

Authors:  M Bhavnani; D Lloyd; J Marples; K Pendry; M Worwood
Journal:  J Clin Pathol       Date:  2006-05       Impact factor: 3.411

7.  Iron loading and morbidity among relatives of HFE C282Y homozygotes identified either by population genetic testing or presenting as patients.

Authors:  C A McCune; D Ravine; K Carter; H A Jackson; D Hutton; J Hedderich; M Krawczak; M Worwood
Journal:  Gut       Date:  2005-09-20       Impact factor: 23.059

8.  Normal iron metabolism and the pathophysiology of iron overload disorders.

Authors:  Chiang W Siah; John Ombiga; Leon A Adams; Debbie Trinder; John K Olynyk
Journal:  Clin Biochem Rev       Date:  2006-02

9.  Reverse cascade screening of newborns for hereditary haemochromatosis: a model for other late onset diseases?

Authors:  E Cadet; D Capron; M Gallet; M-L Omanga-Léké; H Boutignon; C Julier; K J H Robson; J Rochette
Journal:  J Med Genet       Date:  2005-05       Impact factor: 6.318

Review 10.  Screening for hemochromatosis: patients with liver disease, families, and populations.

Authors:  Sumedha P Galhenage; Charlie H Viiala; John K Olynyk
Journal:  Curr Gastroenterol Rep       Date:  2004-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.